LumiThera Inc., a Seattle, WA-based commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and diseases, closed the 2nd tranche of its Series C round of financing.
The company has now raised over $10M in the current C round, which was led by WaterStar Capital, with participation from Nikon Corporation.
The company intends to use the proceeds to support further clinical testing and commercialization of its Valeda® Light Delivery System for the treatment of dry Age-related Macular Degeneration (AMD).
Led by Clark Tedford, Ph.D., President and CEO, LumiThera is a commercial-stage medical device company focused on treating people affected by ocular disorders and diseases including dry AMD, a leading cause of blindness in adults over 65. The Valeda Light Delivery System has been granted authorization to use the CE Mark by an EU Notified Body as required for commercial use in the European Economic Area only. It is not approved for use by the Food & Drug Administration (FDA) in the USA. The company is currently conducting prospective, randomized, double masked, clinical trials in dry AMD subjects.